Melinda Decker is a global biopharmaceutical and digital health leader with a mix of commercial and R&D expertise. She is currently Chief Commercial Officer of Mymee, Inc., a digital care company that empowers those who suffer from autoimmune disease to reclaim their health. Mymee combines a mobile app, data analytics, and certified health coaches to help identify triggers for disease symptoms, to improve the quality of life for those living with autoimmune diseases.
Melinda also serves as an advisor to MIT’s Health Science & Technology program and to several companies focused on digital health. She has broad therapeutic experience with biologic, small molecule and digital health products, across both specialty and primary care, and with both global and local markets. She has a solid background in digital therapeutics, digital health and digital marketing, and previously held leadership roles at both Pfizer and AstraZeneca.
Melinda holds an MS in Biochemical Engineering and an MBA in Finance and Marketing.